Brean Murray Ups Keryx (KERX) Target to $5 Following Zerenex OLE Trial Results
Tweet Send to a Friend
An analyst at Brean Murray raised his price target on shares of Keryx Pharma (Nasdaq: KERX) from $3 to $5 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
